Pegfilgrastim
Neulasta, Neulasta Onpro (pegfilgrastim) is a protein pharmaceutical. Pegfilgrastim was first approved as Neulasta on 2002-01-31. It is used to treat neutropenia in the USA. It has been approved in Europe to treat neoplasms and neutropenia. The pharmaceutical is active against granulocyte colony-stimulating factor receptor.
Trade Name | Neulasta |
---|---|
Common Name | Pegfilgrastim |
Indication | neoplasms, neutropenia |
Drug Class | Colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF); PEGylated compounds |
